(Q42862031)

8 November 2017

title

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel (English)

1 reference

8 November 2017

1 reference

2

I Vergote

1 reference

8 November 2017

P Hoskins

1

1 reference

8 November 2017

A Cervantes

3

1 reference

8 November 2017

D Tu

4

1 reference

8 November 2017

G Stuart

5

1 reference

8 November 2017

P Zola

6

1 reference

8 November 2017

A Poveda

7

1 reference

8 November 2017

D Provencher

8

1 reference

8 November 2017

D Katsaros

9

1 reference

8 November 2017

B Ojeda

10

1 reference

8 November 2017

P Ghatage

11

1 reference

8 November 2017

R Grimshaw

12

1 reference

8 November 2017

A Casado

13

1 reference

8 November 2017

L Elit

14

1 reference

8 November 2017

C Mendiola

15

1 reference

8 November 2017

A Sugimoto

16

1 reference

8 November 2017

V D'Hondt

17

1 reference

8 November 2017

A Oza

18

1 reference

8 November 2017

J R Germa

19

1 reference

8 November 2017

M Roy

20

1 reference

8 November 2017

L Brotto

21

1 reference

8 November 2017

D Chen

22

1 reference

8 November 2017

E A Eisenhauer

23

1 reference

8 November 2017

language of work or name

English

0 references

publication date

11 October 2010

1 reference

Journal of the National Cancer Institute

8 November 2017

published in

1 reference

8 November 2017

volume

102

1 reference

8 November 2017

issue

20

1 reference

8 November 2017

page(s)

1547-1556

1 reference

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

8 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ362

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJQ362

1 reference

8 November 2017

1 reference